CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment

Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy

(2020) Mohammad Shahnawaz et al.   NATURE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Blood neurofilament light levels segregate treatment effects in multiple sclerosis

(2020) Bénédicte Delcoigne et al.   NEUROLOGY

Blood Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein

(2020) Barkovits et al.   Cells

A longitudinal study on α‐synuclein in plasma neuronal exosomes as a biomarker for Parkinson’s disease development and progression

(2020) M. Niu et al.   EUROPEAN JOURNAL OF NEUROLOGY

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

Inflammation-related plasma and CSF biomarkers for multiple sclerosis

(2020) Jesse Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

(2020) Nicolas R. Barthélemy et al.   Alzheimers Research & Therapy

CNS-Derived Blood Exosomes as a Promising Source of Biomarkers: Opportunities and Challenges

(2020) Simon Hornung et al.   Frontiers in Molecular Neuroscience

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Tauopathy: A common mechanism for neurodegeneration and Brain Aging

(2019) Pampa Saha et al.   MECHANISMS OF AGEING AND DEVELOPMENT

Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis

(2019) Lucilla Parnetti et al.   Alzheimers Research & Therapy

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration

(2019) Nicholas J. Ashton et al.   Acta Neuropathologica Communications

Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson's disease

(2019) Un Jung Kang et al.   MOVEMENT DISORDERS

Glial activation and inflammation along the Alzheimer’s disease continuum

(2019) Kaja Nordengen et al.   Journal of Neuroinflammation

Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial

(2019) C. R. A. Silveira et al.   BMC Neurology

Temporal evolution of microglia and α-synuclein accumulation following foetal grafting in Parkinson’s disease

(2019) C Warren Olanow et al.   BRAIN

Neurofilament light chain as a biomarker in neurological disorders

(2019) Lorenzo Gaetani et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson’s Disease

(2019) Xiaoli Si et al.   NEUROSCIENCE

New windows into the brain: Central nervous system-derived extracellular vesicles in blood

(2019) Min Shi et al.   PROGRESS IN NEUROBIOLOGY

Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis

(2019) Silvia Paciotti et al.   CLINICA CHIMICA ACTA

Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid

(2019) Longfei Jia et al.   Alzheimers & Dementia

Parkinson's and Lewy body dementia CSF biomarkers

(2019) Lucilla Parnetti et al.   CLINICA CHIMICA ACTA

Blood NfL

(2019) Chin-Hsien Lin et al.   NEUROLOGY

Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood

(2019) Robert Hendricks et al.   Bioanalysis

Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis

(2019) Kjetil Bjornevik et al.   JAMA Neurology

The vicious cycle between α ‐synuclein aggregation and autophagic‐lysosomal dysfunction

(2019) Giovanni Bellomo et al.   MOVEMENT DISORDERS

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease

(2019) Maria João Leitão et al.   Alzheimers Research & Therapy

Serum neurofilament light chain as a preclinical marker of neurodegeneration

(2019) Lucilla Parnetti et al.   LANCET NEUROLOGY

Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study

(2019) Emma L van der Ende et al.   LANCET NEUROLOGY

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

The genetic architecture of mitochondrial dysfunction in Parkinson’s disease

(2018) S. B. Larsen et al.   CELL AND TISSUE RESEARCH

From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer’s Disease

(2018) Henrik Zetterberg et al.   JOURNAL OF ALZHEIMERS DISEASE

Age-adjusted CSF β2-microglobulin and lactate are increased and ACE is decreased in patients with multiple sclerosis, but only lactate correlates with clinical disease duration and severity

(2018) A. Haarmann et al.   JOURNAL OF NEUROIMMUNOLOGY

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Tau-targeting therapies for Alzheimer disease

(2018) Erin E. Congdon et al.   Nature Reviews Neurology

Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis

(2018) Elmira Agah et al.   PLoS One

The Exosomal/Total α-Synuclein Ratio in Plasma Is Associated With Glucocerebrosidase Activity and Correlates With Measures of Disease Severity in PD Patients

(2018) Silvia Cerri et al.   Frontiers in Cellular Neuroscience

Plasma MCP-1 and Cognitive Decline in Patients with Alzheimer’s Disease and Mild Cognitive Impairment: A Two-year Follow-up Study

(2018) Wei-Ju Lee et al.   Scientific Reports

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation

(2018) Charlotte E. Teunissen et al.   Alzheimers Research & Therapy

Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of “Protein-Misfolding Cyclic Amplification” and “Real-Time Quaking-Induced Conversion” as Diagnostic Tools

(2018) Silvia Paciotti et al.   Frontiers in Neurology

The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non- Responders

(2018) Rodica Balasa et al.   CNS & Neurological Disorders-Drug Targets

Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases

(2018) Ann Brinkmalm et al.   JOURNAL OF NEUROCHEMISTRY

Neurofilaments as biomarkers in neurological disorders

(2018) Michael Khalil et al.   Nature Reviews Neurology

Serum neurofilament light chain in behavioral variant frontotemporal dementia

(2018) Petra Steinacker et al.   NEUROLOGY

New insights into the complex role of mitochondria in Parkinson’s disease

(2018) Anne Grünewald et al.   PROGRESS IN NEUROBIOLOGY

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease

(2018) Claudia Cicognola et al.   ACTA NEUROPATHOLOGICA

Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia

(2018) Lize C Jiskoot et al.   BRAIN

Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity

(2018) Heidi Högel et al.   Multiple Sclerosis Journal

Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease

(2017) Lucia Farotti et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Microglia in Alzheimer’s disease

(2017) Heela Sarlus et al.   JOURNAL OF CLINICAL INVESTIGATION

Evolving concepts in the treatment of relapsing multiple sclerosis

(2017) Giancarlo Comi et al.   LANCET

Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients

(2017) Lucilla Parnetti et al.   MOVEMENT DISORDERS

Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis

(2017) Paolo Eusebi et al.   MOVEMENT DISORDERS

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment

(2017) Cyra E Leurs et al.   Multiple Sclerosis Journal

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod

(2017) Fredrik Piehl et al.   Multiple Sclerosis Journal

Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum

(2017) Laura Cervera-Carles et al.   NEUROBIOLOGY OF AGING

Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers

(2017) Kaitlin B. Casaletto et al.   NEUROLOGY

Serum neurofilament light in familial Alzheimer disease

(2017) Philip S.J. Weston et al.   NEUROLOGY

Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease

(2017) Koen Poesen et al.   NEUROLOGY

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

(2017) Lenka Novakova et al.   NEUROLOGY

Review: Tau in biofluids - relation to pathology, imaging and clinical features

(2017) H. Zetterberg   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

CSF profile in primary progressive multiple sclerosis: Re-exploring the basics

(2017) Ahmed Abdelhak et al.   PLoS One

Should We Stop Saying ‘Glia’ and ‘Neuroinflammation’?

(2017) Roser Masgrau et al.   TRENDS IN MOLECULAR MEDICINE

Neurofilaments and Neurofilament Proteins in Health and Disease

(2017) Aidong Yuan et al.   Cold Spring Harbor Perspectives in Biology

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

(2017) Niklas Mattsson et al.   JAMA Neurology

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment

(2017) Cyra E Leurs et al.   Multiple Sclerosis Journal

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod

(2017) Fredrik Piehl et al.   Multiple Sclerosis Journal

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease

(2016) Niklas Mattsson et al.   EMBO Molecular Medicine

Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer’s disease

(2016) Claudio Liguori et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression

(2016) Maria Albanese et al.   Journal of Neuroinflammation

A New Glucocerebrosidase Chaperone Reduces  -Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism

(2016) E. Aflaki et al.   JOURNAL OF NEUROSCIENCE

Activation of  -Glucocerebrosidase Reduces Pathological  -Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons

(2016) J. R. Mazzulli et al.   JOURNAL OF NEUROSCIENCE

Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression

(2016) Nour K. Majbour et al.   MOVEMENT DISORDERS

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis

(2016) Lenka Novakova et al.   Multiple Sclerosis Journal

Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone

(2016) Annika Öhrfelt et al.   Multiple Sclerosis Journal

How neuroinflammation contributes to neurodegeneration

(2016) R. M. Ransohoff   SCIENCE

There's Something Wrong with my MAM; the ER–Mitochondria Axis and Neurodegenerative Diseases

(2016) Sebastien Paillusson et al.   TRENDS IN NEUROSCIENCES

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis

(2016) Lenka Novakova et al.   Multiple Sclerosis Journal

Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone

(2016) Annika Öhrfelt et al.   Multiple Sclerosis Journal

Plasma neurofilament light chain predicts progression in progressive supranuclear palsy

(2016) Julio C. Rojas et al.   Annals of Clinical and Translational Neurology

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

(2016) Magnus Gisslén et al.   EBioMedicine

Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study

(2015) Massimo S. Fiandaca et al.   Alzheimers & Dementia

Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease

(2015) Angela Pyle et al.   ANNALS OF NEUROLOGY

Differentiation and quantification of inflammation, demyelination and axon injury or loss in multiple sclerosis

(2015) Yong Wang et al.   BRAIN

A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes

(2015) N K Magdalinou et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Depletion of microglia and inhibition of exosome synthesis halt tau propagation

(2015) Hirohide Asai et al.   NATURE NEUROSCIENCE

Extracellular vesicles – Their role in the packaging and spread of misfolded proteins associated with neurodegenerative diseases

(2015) Bradley M. Coleman et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer’s disease

(2014) Dietmar Rudolf Thal et al.   ACTA NEUROPATHOLOGICA

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease

(2014) Karen E. Murphy et al.   BRAIN

Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis

(2014) Liang Gao et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease

(2014) C Liguori et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis

(2014) Manuel A. Friese et al.   Nature Reviews Neurology

CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival

(2014) T. Skillback et al.   NEUROLOGY

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of Misfolded Aβ Oligomers for Sensitive Biochemical Diagnosis of Alzheimer’s Disease

(2014) Natalia Salvadores et al.   Cell Reports

Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF

(2013) Francois Bernier et al.   Alzheimers & Dementia

Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease

(2013) Petar Podlesniy et al.   ANNALS OF NEUROLOGY

Quantification of the Concentration of Aβ42 Propagons during the Lag Phase by an Amyloid Chain Reaction Assay

(2013) Paolo Arosio et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies

(2013) S. Pablo Sardi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease

(2012) Lynne I. McGuire et al.   ANNALS OF NEUROLOGY

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

(2012) Vladimir Coric et al.   ARCHIVES OF NEUROLOGY

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

(2012) Bengt Winblad et al.   LANCET NEUROLOGY

The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders

(2012) Koichi Wakabayashi et al.   MOLECULAR NEUROBIOLOGY

BACE1 Inhibition Induces a Specific Cerebrospinal Fluid β-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System

(2012) Niklas Mattsson et al.   PLoS One

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

(2010) Zhen Hong et al.   BRAIN

Neuronal MCP-1 Mediates Microglia Recruitment and Neurodegeneration Induced by the Mild Impairment of Oxidative Metabolism

(2010) Guang Yang et al.   BRAIN PATHOLOGY

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis

(2010) M. Axelsson et al.   JOURNAL OF NEUROLOGY

The Role of Microglia in Antibody-Mediated Clearance of Amyloid-Beta from the Brain

(2009) Dave Morgan   CNS & Neurological Disorders-Drug Targets

Cerebrospinal fluid β-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies

(2009) L. Parnetti et al.   NEUROBIOLOGY OF DISEASE

Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation

(2008) Laura Piccio et al.   BRAIN

Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression

(2008) William T. Regenold et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?

(2008) Annika Öhrfelt et al.   NEUROSCIENCE LETTERS